MiSight® 1 day
The first FDA-approved treatment to slow the progression of myopia in children as young as 8 years old.*1 Original MiSight® 1 day contact lenses are the #1 most fitted soft contact lenses for myopia control in children†2 and backed by a 7-year clinical trial – the longest-running soft contact lens study among children.
*Compared to a single vision 1 day lens over a 3-year period.
† Based on available fit data in the UK and US for patients under 20
1. Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567.
2. CVI Data on file 2025, MiSight 1 day and similar lens types - patients under 20.
Visit the MiSight® 1 day website.
Information
MiSight® 1 day contact lenses are specifically designed for children with myopia.*
Visit the MiSight® 1 day website.
Features and Benefits
- Tested and clinically proven to slow the progression of myopia by 59% on average†1
- ‘Always on’ myopia control helps to achieve the required wear time‡2
- ActivControl® Technology is backed by the MiSight® 1 day 7-year clinical trial.*1,3,4
- FDA approved* for kids aged 8-12 at the initiation of treatment
- International clinical study found myopia control benefits are retained after treatment ends§4,5
- Child-friendly, easy to fit and easy to useà1,6
- Ideal for children’s active lifestyles7
- Contact lenses can help improve children’s self-perception of their appearance, athletic competence, and social acceptance7
Technology
ActivControl® Technology helps control both axial length and myopia progression in children while fully correcting refractive error.†1
ActivControl® Technology utilizes an optic zone concentric ring design with alternating vision correction zones and treatment zones. Two zones are vision correction zones with the label power of the contact lens, and the other two zones are treatment zones with 2 diopters of defocus to slow the progression of myopia.
Myopia management
Childhood myopia is a chronic and progressive disease growing in both prevalence and severity.8 There is an urgency to act now as myopia worsening is irreversible9 and 1 in 2 children born today could have myopia by age 20.8 Addressing a child’s myopia early helps to reduce the risk of myopia-related vision complications later in life, including retinal detachment, myopic maculopathy, glaucoma, and cataracts.10-13
Product disclaimer
It is up to the individual eye care practitioner to be aware of regulatory requirements for prescribing in their country of practice, and also be aware that not all products are available in all countries.
Plastic used in participating CooperVision® soft contact lens products is determined by the weight of plastic in the blister, the lens, and the secondary package, including laminates, adhesives, and auxiliary inputs (e.g. ink). The determination does not include plastic used during the manufacturing process for both these products and their packaging.¶14
*Indications for use (US Only): MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
†Compared to a single vision 1 day lens over a 3-year period.
‡In clinical study, mean weekday wear time increased from 12.8 hours/day at 6-months to 13.9 hours/day at 6-years with a mean of >6.5 days/week.
§Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates.
Disclaimer (US only): The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval for MiSight® 1 day.
àInitial CL BVP selection and observation of fit follows same fitting protocol for single vision CLs; fit success rate same with MiSight® 1 day and Proclear® 1 day.
¶Plastic used in participating CooperVision® soft contact lens products is determined by the weight of plastic in the blister, the lens, and the secondary package, including laminates, adhesives, and auxiliary inputs (e.g. ink). The determination does not include plastic used during the manufacturing process for both these products and their packaging.
- Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567.
- Woods J et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391.
- Chamberlain P, et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. OVS 2022 Mar 1;99(3):204-212.
- Chamberlain P, et al. Myopia Progression in Children on cessation of Dual-Focus contact lens wear: MiSight 1 day 7-year findings. Optom Vis Sci 2021;98:E-abstract 210049.
- Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130.
- CVI data on file 2018.
- Walline J, et al. Randomized trial of the effect of contact lens wear on self-perception in children. Optom Vis Sci. 2009 Mar;86(3):222-32.
- Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042
- K. Zadnik et al. Factors Associated with Rapid Myopia Progression in School-aged Children. IOVS 2004;45(13):2306.
- Xu L et al. High myopia and glaucoma susceptibility, the Beijing Eye Study. Ophthalmology. 2007;114(2):216-20.
- Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. PRER 2013;31(6):622-60.
- Younan C, et al. Myopia and incident cataract and cataract surgery: the blue mountains eye study. IVOS 2002;43(12):3625-3632.
- Chen SJ, et al. Prevalence and associated risk factors of myopic maculopathy in elderly Chinese: the Shihpai eye study. IOVS 2012;53(8):4868-73.
- CVI data on file, 2024.
MiSight 1-day.
CooperVision resources
New six year MiSight® 1 day research interview
In this interview, Paul Gifford and Kate Gifford of Myopia Profile chat to Arthur Bradley and Paul Chamberlain, CooperVision R&D leaders, about their newly published paper in Ophthalmic and Physiological Optics which explores a novel analysis on the cumulative treatment effect and efficacy of MiSight 1 day, from the six year clinical study.
One Thing - my myopia management journey
As part of Myopia Action Month in September 2023, CooperVision asked myopia experts around the world "What's the one thing that motivated you to start with myopia management?" Listen to leaders in the field discuss their journey into myopia management, and what they have learnt along the way.
The MiSight® 1 day Story
MiSight® 1 day contact lenses hold the largest body of evidence for childhood myopia management with soft contact lenses - listen to experts and researchers discuss the science behind MiSight® 1 day , and how this extensive and compelling research translates into practice.